Aptose Biosciences featured data from its TUSCANY trial at the ASH Annual Meeting, showing high efficacy rates and MRD-negative remissions in AML patients. The TUS+VEN+AZA triplet therapy achieved a 100% response rate at higher doses, including for patients with diverse mutations. Safety remains a key feature of TUS-based therapies, making them a promising option for AML treatment. The therapy also demonstrated efficacy in FLT3 wildtype subjects and those with TP53/complex karyotype, RAS, and MDS-related mutations. The ongoing TUSCANY study aims to address unmet needs in AML treatment by targeting a broad range of patient populations.

Read more at GlobeNewswire: Aptose’s Tuspetinib Triple Drug Therapy Featured at the